Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium Academic Article uri icon

Overview

MeSH Major

  • Gene Expression Regulation
  • Tumor Suppressor Protein p53

abstract

  • In this large real-world cohort we observed that VDZ was well tolerated and effective in achieving key clinical outcomes.

authors

publication date

  • June 27, 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1038/s41395-018-0162-0

PubMed ID

  • 29946178

Additional Document Info

start page

  • 1

end page

  • 10